A TLR7/8 agonist-chitosan conjugate as an adjuvant for carbohydrate-based anticancer vaccine development
Xu-Guang Yin1, Guo-Zuo Tong1, Si-Qi Huang1
1Center for Drug Delivery System Research, School of Medicine, Shaoxing University, 900 Chengnan Avenue, Shaoxing, Zhejiang 312000, China. kewuzhu@usx.edu.cn.
Abstract:
The TLR7/8 agonist imidazoquinoline (IMDQ), 1-(4-(amino-methyl)benzyl)-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-4-amine, conjugated to chitosan was found to be a superior adjuvant to aluminum salts for vaccination against tumor-associated carbohydrate antigens.
More Related Videos
12:53Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development
Published on: March 16, 2022
09:15Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Related Concept Videos
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
